GSK close to US$1b deal for biotech company IDRx, Bloomberg reportsGSK plc is in talks to buy biotech company IDRx, people with knowledge of the matter said, a deal that would see the British drugmaker further boost its growing oncology portfolio.
The purchase could value privately owned IDRx at as much as US$1 billion (RM4.5 billion), said the people, who asked not to be identified because the information is private. The negotiations are still ongoing and there is no guarantee that a deal will be agreed. The Financial Times first reported on the potential deal.